Back to Search Start Over

Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison.

Authors :
de Miguel, Diego
Ramirez‐Labrada, Ariel
Uranga, Iratxe
Hidalgo, Sandra
Santiago, Llipsy
Galvez, Eva María
Arias, Maykel
Pardo, Julián
Source :
FEBS Journal; Aug2022, Vol. 289 Issue 15, p4398-4415, 18p
Publication Year :
2022

Abstract

Cytotoxic lymphocytes (CLs), and more specifically Tc and NK cells, are the main executors of cell death in the immune system, playing a key role during both immunosurveillance and immunotherapy. These cells induce regulated cell death (RCD) by different mechanisms, being granular exocytosis and expression of death ligands the most prominent and best characterized ones. Apoptosis, a traditionally considered low‐inflammatory type of cell death, has been accepted for years as the paradigm of RCD induced by CLs. However, several recent studies have demonstrated that NK cells and Tc cells can also induce more inflammatory forms of cell death, namely, necroptosis, pyroptosis, and ferroptosis. Activation of these highly inflammatory types of cell death appears to critically contribute to the activation of a successful antitumour immune response. Additionally, the role of specific cell death pathways in immunogenic cell death is still under intense debate, especially considering the interconnections with other inflammatory forms of cell death. These evidences, together with the advent of new cancer immunotherapies, highlight the necessity to deepen our understanding of the link between the cell death triggered by CLs and inflammation. This knowledge will be instrumental to maximize the antitumour potential of immunotherapies, minimizing deleterious effects associated with these treatments. In this review, we will briefly summarize the main features of apoptosis, necroptosis, pyroptosis and ferroptosis, to subsequently discuss the most recent evidences about the role of these RCD pathways during the elimination of cancer cells mediated by CLs and its modulation to increase the efficacy of cancer immunotherapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1742464X
Volume :
289
Issue :
15
Database :
Complementary Index
Journal :
FEBS Journal
Publication Type :
Academic Journal
Accession number :
158341225
Full Text :
https://doi.org/10.1111/febs.16093